Table 3.

Main studies evaluating the relationships between ACE I/D genotypes and response to ACE inhibitor therapy in nondiabetic renal disease

Ruggenenti et al. (35), 2000aPerna et al. (19), 2000aEssen et al. (37), 1996van der Kleij et al. (56), 1997van der Kleij et al. (57), 1997Haas et al. (58), 1998Yoshida et al. (55), 1995Moriyama et al. (54), 1995
No. of patients352212816188365336
Follow-up (yr)64.730.20.20.510.25
Patient characteristicsPersistent proteinuriaPersistent proteinuriaProteinuriaStable proteinuriaStable proteinuriaProtenuric glomerular diseaseIgA nephropathyProteinuria
Baseline characteristics of genotype groupsComparableComparableDifferent GFRComparableComparable?Comparable?
Treatment in genotype groupsComparableComparableComparableComparableComparable???
Adjustments for relevant covariatesYesYes????Yes?
Effect of ACE inhibitor therapySlower ΔGFR and reduced ESKD in women and in DD menSlower ΔGFR and reduced ESKD in DD, non significant effect in ID and IIProteinuria reduction and slower ΔGFR in ID and IISimilar effects on proteinuria and GFRSimilar proteinuria reductionbProteinuria reduction in ID and IIProteinuria reduction in DDMore reduced proteinuria in ID + II versus DD
  • ?, insufficient information.

  • a Data retrieved from the Ramipril Efficacy in Nephropathy (REIN) trial.

  • b Less albuminuria reduction in DD with high sodium excretion.